Most Recent
Regeneron loses opposition to Kymab’s patent for human rats
Intellectual Property 2019-08-01 2:30 pm By Miklos Bolza

US biotechnology firm Regeneron Pharmaceuticals has lost its opposition to a proposed patent by UK biopharmaceutical company Kymab for a method of producing an animal with part-human DNA.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

‘Guinea pig’ judge pushes off Country Care cartel trial to next year
Competition & Consumer Protection 2019-07-30 9:34 pm By Miklos Bolza

A six-week trial set to start in October in the cartel case against mobility equipment provider Country Care Group has been vacated and rescheduled to next year, as the judge overseeing the case quipped that he was either the “canary or the guinea pig” in the landmark criminal proceeding.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Samsung Bioepsis sues to invalidate Humira biosimilar
Intellectual Property 2019-07-29 3:38 pm By Miklos Bolza

Korean drug company Samsung Bioepis has filed a lawsuit seeking to invalidate German drug company Fresenius Kadi’s patent for a biosimilar of blockbuster arthritis drug Humira.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Judge meets further resistance from doctors group in Ethicon pelvic mesh class action
Product Liability 2019-07-26 9:54 pm By Amelia Birnie

A judge has ordered a leading doctor’s professional body to hand over its member list to the applicants in the Ethicon pelvic mesh class action, after the organisation tried to argue its physical member book didn’t strictly fall within the terms of a court order.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Cipla, Mylan settle lawsuit over ‘deceptive’ fenofibrate packaging
Intellectual Property 2019-07-25 12:48 pm By Cat Fredenburgh

Mylan and Cipla have reached a speedy resolution of a consumer lawsuit accusing Cipla of copying the get-up of Mylan’s blockbuster cholesterol drug Lipidil.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Online drug supplier Peptides Clinic hit with $10M fine for advertising breaches
Healthcare 2019-07-23 9:49 pm By Christine Caulfield

A judge has slapped a $10 million fine on online supplement company Peptide Clinics for advertising prescription-only drugs in breach of the Therapeutic Goods Act.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Mylan fires another shot at Cipla in generic Lipidil battle
Competition & Consumer Protection 2019-07-22 9:35 pm By Cat Fredenburgh

Mylan has launched a lawsuit against Cipla for allegedly copying the get-up of its blockbuster cholesterol drug Lipidil, after losing a bid to block Cipla and Sun Pharma from selling generic versions of the drug while it appeals a ruling invalidating several claims of its patents.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Boehringer wins time to oppose Intervet patent after lawyers botched deadline
Intellectual Property 2019-07-22 4:56 pm By Cat Fredenburgh

A unit of Boehringer Ingelheim has been given more time to oppose a proposed patent by rival drug maker Intervet, after the German drug company’s lawyers sent an email with the wrong opposition deadline.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Judge refuses ‘queue jumping’ request in Sirtex CEO insider trading case
White Collar 2019-07-19 1:12 pm By Miklos Bolza

An application by the former boss of Sirtex Medical for a sentencing date in the insider trading case against him has raised the ire of a NSW District Court judge, who called the bid premature and an attempt to jump the queue.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Aged care provider Estia Health hit with shareholder class action
Class Actions 2019-07-17 2:09 pm By Amelia Birnie

Residential aged care provider Estia Health says it will “vigorously defend” a class action filed by Phi Finney McDonald on behalf of shareholders who allege the company failed to disclose serious commercial difficulties with its acquisition strategy.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?